89 related articles for article (PubMed ID: 9041177)
1. 4-Demethylpenclomedine, an antitumor-active, potentially nonneurotoxic metabolite of penclomedine.
Waud WR; Tiwari A; Schmid SM; Shih TW; Strong JM; Hartman NR; O'Reilly S; Struck RF
Cancer Res; 1997 Mar; 57(5):815-7. PubMed ID: 9041177
[TBL] [Abstract][Full Text] [Related]
2. Acyl derivatives of demethylpenclomedine, an antitumor-active, non-neurotoxic metabolites of penclomedine.
Struck RF; Tiwari A; Friedman HS; Keir S; Morgan LR; Waud WR
Cancer Chemother Pharmacol; 2001 Jul; 48(1):47-52. PubMed ID: 11488524
[TBL] [Abstract][Full Text] [Related]
3. Thiolo-, thiono- and dithiocarbonate and thiocarbamate derivatives of demethylpenclomedine as novel anticancer agents.
Struck RF; Waud WR
Cancer Chemother Pharmacol; 2006 Jan; 57(2):180-4. PubMed ID: 16096790
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and antitumor activity of several new analogues of penclomedine and its metabolites.
Tiwari A; Riordan JM; Waud WR; Struck RF
J Med Chem; 2002 Feb; 45(5):1079-85. PubMed ID: 11855988
[TBL] [Abstract][Full Text] [Related]
5. Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents.
Morgan LR; Struck RF; Waud WR; LeBlanc B; Rodgers AH; Jursic BS
Cancer Chemother Pharmacol; 2009 Sep; 64(4):829-35. PubMed ID: 19255760
[TBL] [Abstract][Full Text] [Related]
6. Determination of the phamacophore of penclomedine, a clinically-evaluated antitumor pyridine derivative.
Tiwari A; Waud W; Struck R
Bioorg Med Chem; 2002 Nov; 10(11):3593-8. PubMed ID: 12213474
[TBL] [Abstract][Full Text] [Related]
7. Preclinical antitumor activity of penclomedine in mice: cross-resistance, schedule dependence, and oral activity against tumor xenografts in brain.
Harrison SD; Plowman J; Dykes DJ; Waud WR; Griswold DP
Cancer Res; 1991 Apr; 51(8):1979-83. PubMed ID: 2009516
[TBL] [Abstract][Full Text] [Related]
8. The in vitro metabolism of penclomedine in mouse, rat, and human systems.
Hartman NR; Leo KU; Brewer TG; Strong JM
Drug Metab Dispos; 1998 Jun; 26(6):513-9. PubMed ID: 9616185
[TBL] [Abstract][Full Text] [Related]
9. The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellum.
O'Reilly S; O'Hearn E; Struck RF; Rowinsky EK; Molliver ME
Invest New Drugs; 2003 Aug; 21(3):269-79. PubMed ID: 14578677
[TBL] [Abstract][Full Text] [Related]
10. Preclinical antitumor activity of an alpha-picoline derivative, penclomedine (NSC 338720), on human and murine tumors.
Plowman J; Harrison SD; Dykes DJ; Paull KD; Narayanan VL; Tobol HK; Martin J; Griswold DP
Cancer Res; 1989 Apr; 49(8):1909-15. PubMed ID: 2702634
[TBL] [Abstract][Full Text] [Related]
11. Murine pharmacokinetics and metabolism of penclomedine [3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine, NSC 338720].
Reid JM; Mathiesen DA; Benson LM; Kuffel MJ; Ames MM
Cancer Res; 1992 May; 52(10):2830-4. PubMed ID: 1581896
[TBL] [Abstract][Full Text] [Related]
12. Murine and human in vivo penclomedine metabolism.
Hartman NR; O'Reilly S; Rowinsky EK; Collins JM; Strong JM
Clin Cancer Res; 1996 Jun; 2(6):953-62. PubMed ID: 9816256
[TBL] [Abstract][Full Text] [Related]
13. Tissue and tumor distribution of C-penclomedine in rats.
O'Reilly S; Hartman NR; Grossman SA; Strong JM; Struck RF; Eller S; Lesser GJ; Donehower RC; Rowinsky EK
Clin Cancer Res; 1996 Mar; 2(3):541-8. PubMed ID: 9816201
[TBL] [Abstract][Full Text] [Related]
14. Biochemical pharmacology of penclomedine (NSC-338720).
Benvenuto JA; Hittelman WN; Zwelling LA; Plunkett W; Pandita TK; Farquhar D; Newman RA
Biochem Pharmacol; 1995 Oct; 50(8):1157-64. PubMed ID: 7488229
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy.
Liu G; Berlin J; Tutsch KD; Van Ummersen L; Dresen A; Marnocha R; Arzomanian R; Alberti D; Feierabend C; Binger K; Wilding G
Clin Cancer Res; 2002 Mar; 8(3):706-11. PubMed ID: 11895899
[TBL] [Abstract][Full Text] [Related]
16. Bioavailability of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine.
O'Reilly S; Hartman NR; Bowling KM; Rowinsky EK; Donehower RC; Collins J; Strong JM
Cancer Chemother Pharmacol; 2001 Sep; 48(3):223-8. PubMed ID: 11592344
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid tumors.
O'Reilly S; Grochow LB; Donehower RC; Chen TL; Bowling K; Hartman NR; Struck RF; Rowinsky EK
J Clin Oncol; 1997 May; 15(5):1974-84. PubMed ID: 9164209
[TBL] [Abstract][Full Text] [Related]
18. Preliminary development and evaluation of a parenteral emulsion formulation of penclomedine (NSC-338720; 3,5-dichloro-2,4-dimethoxy-6-trichloromethylpyridine): a novel, practically water insoluble cytotoxic agent.
Prankerd RJ; Frank SG; Stella VJ
J Parenter Sci Technol; 1988; 42(3):76-81. PubMed ID: 3216265
[No Abstract] [Full Text] [Related]
19. Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic alpha-picoline derivative, administered intravenously.
Jodrell DI; Bowman A; Stewart M; Dunlop N; French R; MacLellan A; Cummings J; Smyth JF
Br J Cancer; 1998 Mar; 77(5):808-11. PubMed ID: 9514062
[TBL] [Abstract][Full Text] [Related]
20. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
